What's Happening?
The Sabin Vaccine Institute has delivered over 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to aid in the country's response to its first-ever Marburg virus outbreak. The vaccine is
part of a Phase 2 clinical trial to assess its safety and efficacy. The U.S. government, through the Biomedical Advanced Research and Development Authority (BARDA), supports the development and manufacture of this vaccine. The trial targets high-risk healthcare workers and individuals in contact with infected persons.
Why It's Important?
The deployment of the investigational Marburg vaccine to Ethiopia is a critical step in addressing the outbreak of this highly contagious and deadly virus. With no licensed vaccines or treatments currently available for Marburg, this initiative represents a significant effort to contain the virus and protect public health. The collaboration between Sabin, the Ethiopian Ministry of Health, and international partners underscores the importance of global cooperation in managing infectious disease outbreaks and advancing vaccine development.
